论文部分内容阅读
目的研究并探讨组织因子途径抑制物-2(TFPI-2)的表达对宫颈癌的影响。方法选取2012年10月-2014年10月该院收治的116例宫颈癌患者为研究对象,其中68例患者为宫颈鳞癌,48例患者为宫颈上皮内肿瘤(CIN),并选取12例健康体检者为对照组。采集这128例患者的宫颈组织切片标本,应用免疫组化染色法对标本中的TFPI-2进行检验。采集宫颈癌患者宫颈肿瘤中发育情况较好的癌细胞,应用MTT法检测宫颈癌细胞的增殖情况,观察宫颈癌细胞的凋亡情况。结果对照组、CIN组以及宫颈鳞癌组患者宫颈组织切片标本中的TFPI-2表达阳性呈顺次逐渐降低的趋势,3组患者之间两两比较差异均有统计学意义(P<0.05)。随着标本培养时间的延长,转染前和转染后TFPI-2的表达更具有差异性。基因转染后宫颈癌细胞凋亡情况明显多于基因转染前。结论随着时间的延长和病情的逐渐恶化,TFPI-2的表达呈逐渐降低趋势,进行基因转染的TFPI-2能够有效抑制宫颈癌细胞增殖,并有效促进宫颈癌细胞的凋亡。TFPI-2的表达减少提示宫颈癌患者的癌变可能发生恶化,而对TFPI-2进行基因转染可以作为宫颈癌患者治疗的新靶点。
Objective To study and investigate the effect of tissue factor pathway inhibitor-2 (TFPI-2) on cervical cancer. Methods A total of 116 cases of cervical cancer admitted to our hospital from October 2012 to October 2014 were selected as study subjects. Among them, 68 cases were squamous cell carcinoma of the cervix, 48 cases were cervical intraepithelial neoplasia (CIN) and 12 cases were healthy Physical examination for the control group. Cervical tissue sections of 128 patients were collected and tested for TFPI-2 using immunohistochemical staining. Cervical cancer patients with cervical cancer better development of cancer cells collected, the application of MTT assay of cervical cancer cell proliferation observed cervical cancer cell apoptosis. Results The positive expression of TFPI-2 in the control group, CIN group and cervical squamous cell carcinoma group showed a gradually decreasing trend in sequence. The differences among the three groups were statistically significant (P <0.05) . With the extension of culture time, the expression of TFPI-2 was more different before and after transfection. Apoptosis of cervical cancer cells after gene transfection was significantly more than before gene transfection. Conclusion The expression of TFPI-2 gradually decreases with the prolongation of time and the progressive deterioration of the disease. TFPI-2 gene transfection can effectively inhibit the proliferation of cervical cancer cells and effectively promote the apoptosis of cervical cancer cells. The decreased expression of TFPI-2 suggests that the carcinogenesis of cervical cancer patients may be deteriorated. Gene transfection of TFPI-2 may be a new target for the treatment of cervical cancer patients.